Venture Life Group PLC Director/PDMR Shareholding (3561Z)

TIDMVLG

RNS Number : 3561Z

Venture Life Group PLC

09 January 2020

9 January 2020

Venture Life Group plc

("Venture Life" or the "Group")

Director dealings

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Sharon Collins, Chief Commercial Officer, purchased 283,600 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a price of 35.75 pence per share on 8 January 2020 and a further 71,020 Ordinary Shares at a price of 35.12 pence per share on 9 January 2020.

Following these purchases, Sharon Collins is interested in 2,019,953 Ordinary Shares, representing approximately 2.41% of the issued share capital of the Company.

For further information, please contact:

 
                                                      +44(0) 1344 
 Venture Life Group plc                                578004 
 Jerry Randall, Chief Executive Officer 
 
                                                      [phone] 
 Cenkos Securities plc (Nomad and Broker)             8900 
 Mark Connelly / Stephen Keys / Cameron MacRitchie 
  (Corporate Finance) 
 Russell Kerr / Michael Johnson (Sales) 
 
                                                       [phone] 
  Alma PR                                               0205 
 Hilary Buchanan / Helena Bogle / Jessica Joynson 
 
 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

 
  1   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Sharon Collins 
     ------------------------  ----------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status           Chief Commercial Officer 
     ------------------------  ----------------------------------------- 
 b)   Initial notification      Initial Notification 
       /Amendment 
     ------------------------  ----------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                      Venture Life Group plc 
     ------------------------  ----------------------------------------- 
 b)   LEI                       213800S8CZUPLAB2KC70 
     ------------------------  ----------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description               Ordinary Shares of 0.3p each in Venture 
       of the financial          Life Group plc 
       instrument, 
       type of instrument 
     ------------------------  ----------------------------------------- 
 b)   Identification            GB00BFPM8908 
       code 
     ------------------------  ----------------------------------------- 
 c)   Nature of the             Purchase of Ordinary Shares 
       transaction 
     ------------------------  ----------------------------------------- 
 d)   Price and volumes           Price                Volume 
                                        1. GBP0.3575         1. 283,600 
                                         2. GBP0.3512         2. 71,020 
                                                       ---------------- 
     ------------------------  ----------------------------------------- 
 d)   Aggregated information 
       - Aggregated               N/A - single trades 
       volume 
       - Price 
     ------------------------  ----------------------------------------- 
 e)   Date of the                    1. 8(th) January 2020 
       transaction 
                                      2. 9(th) January 2020 
     ------------------------  ----------------------------------------- 
 f)   Place of the              London Stock Exchange 
       transaction 
     ------------------------  ----------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHFLFFRLSIAIII

(END) Dow Jones Newswires

January 09, 2020 11:28 ET (16:28 GMT)